The blood–brain barrier (BBB) restricts the transport of potential therapeutic moieties to the
brain. Direct targeting the brain via olfactory and trigeminal neural pathways by passing the …

Central nervous system (CNS) diseases are among the most difficult to treat, mainly
because the vast majority of the drugs fail to cross the blood-brain barrier (BBB) or to reach …

While small interfering RNAs (siRNAs) have been rapidly appreciated to silence genes,
efficient and non-toxic vectors for primary cells and for systemic in vivo delivery are lacking …

Protein therapy exhibits several advantages over small molecule drugs and is increasingly
being developed for the treatment of disorders ranging from single enzyme deficiencies to …

Metabolomics represents the global assessment of metabolites in a biological sample and
reports the closest information to the phenotype of the biological system under study …

Development of effective non-invasive drug delivery systems is of great importance to the
treatment of Alzheimer's diseases and has made great progress in recent years. In this work …

Metabolomics first burst into the toxicology arena approximately 10–12 years ago,
experiencing rapid growth as a science in the intervening period (Fig. 1). Though …

Metabolomics use in toxicology is rapidly increasing, particularly owing to advances in mass
spectroscopy, which is widely used in the life sciences for phenoty** disease states …

Delivery of proteins/peptides to the gastrointestinal (GI) tract via peroral/oral route involves
tremendous challenges due to unfavorable environmental conditions like harsh pH …

Skin penetrating peptides (SPPs) have garnered wide attention in recent years and
emerged as a simple and effective noninvasive strategy for macromolecule delivery into the …